急性冠脉综合征PCI术后阿司匹林停用时机的系统综述与荟萃分析
短程DAPT后P2Y12抑制剂单药降低NACE(RR 0.77;95%CI 0.66-0.89),主要由大出血减少驱动(RR 0.46;95%CI 0.36-0.58),MACE无显著差异,阿司匹林停用最佳时机仍不确定。
要点
- 短程DAPT后P2Y12抑制剂单药较标准DAPT降低NACE,主要因大出血减少。
- 各短程DAPT策略间NACE无显著差异,但阿司匹林1个月内停用排名最高。
- 3个月DAPT在MACE及单项缺血终点排名最高,需个体化权衡出血与缺血风险。
核心结论
- ACS行PCI患者中,短程DAPT后P2Y12抑制剂单药在NACE方面优于标准DAPT。
- 阿司匹林停用最佳时机仍不确定,早期停用可能净获益更大但3个月DAPT缺血结局更优。
研究设计与样本
- 比较短程DAPT(无阿司匹林、<1个月、1个月、3个月DAPT)后P2Y12抑制剂单药与12个月DAPT。
主要发现
- 短程DAPT后P2Y12抑制剂单药较标准DAPT降低NACE(RR 0.77;95%CI 0.66-0.89)。
- 大出血降低(RR 0.46;95%CI 0.36-0.58),为主要驱动因素。
- 网络荟萃分析中除无阿司匹林外各短程DAPT策略均降低NACE,策略间无显著差异。
- 阿司匹林<1个月内停用在主要终点排名最高,3个月DAPT在MACE及单项缺血终点排名最高。
- 各DAPT策略间MACE无显著差异。
关键数值与推荐
- 主要终点为研究定义的净不良临床事件(NACE),为缺血与出血复合终点。
- 次要终点包括大出血和研究定义的主要不良心血管事件(MACE)。
- 采用累积排名曲线下面积(SUCRA)评估最佳策略概率。
临床怎么用
- ACS行PCI后可考虑短程DAPT后P2Y12抑制剂单药以降低出血和净不良事件。
- 阿司匹林停用时机应依据出血与缺血风险个体化决定,早期停用偏向减少出血,3个月DAPT偏向减少缺血。
局限性
- 原文摘要未报告纳入试验的具体设计类型、随访时长及异质性指标。
- 原文摘要未报告各策略两两比较的详细效应量及置信区间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), abbreviated dual antiplatelet therapy (DAPT) reduces bleeding as compared with standard DAPT. Still, the optimal timing of aspirin discontinuation remains uncertain. We aimed to compare the net benefits of aspirin discontinuation timing in short DAPT followed by P2Y12 inhibitor monotherapy versus standard DAPT. METHODS: We performed pairwise and network meta-analyses (NMAs) to directly and indirectly compare short DAPT (aspirin-free, <1 month, 1-month and 3-month DAPT) followed by P2Y12 inhibitor monotherapy with 12-month DAPT. The primary endpoint was study-defined net adverse clinical events (NACE), a composite of ischaemic and bleeding outcomes. Secondary outcomes included major bleeding and study-defined major adverse cardiovascular events (MACE). The probability of being the best strategy was ranked according to the surface under the cumulative ranking curve. RESULTS: 11 trials (n=34 283) were included. Short DAPT followed by P2Y12 inhibitor monotherapy reduced NACE compared with standard DAPT (risk ratio (RR) 0.77; 95% CI 0.66 to 0.89), mainly driven by major bleeding (RR 0.46; 95% CI 0.36 to 0.58). In NMA, all individual short DAPT strategies followed by P2Y12 inhibitor monotherapy, except aspirin-free, reduced NACE, with no significant differences between them. Yet, aspirin discontinuation within<1 month ranked highest for the primary endpoint. No significant difference in MACE was observed among DAPT strategies; however, 3-month DAPT consistently ranked highest for MACE and for individual ischaemic endpoints. CONCLUSIONS: In patients with ACS undergoing PCI, short DAPT followed by P2Y12 inhibitor monotherapy is superior to standard DAPT with respect to NACE. Although a brief period of DAPT appears warranted after ACS, the optimal timing of aspirin discontinuation remains uncertain. While earlier aspirin discontinuation may be associated with greater net clinical benefit owing to reduced bleeding, 3-month DAPT may be associated with more favourable ischaemic outcomes, underscoring the importance of individualising DAPT duration according to bleeding and ischaemic risk. PROSPERO REGISTRATION NUMBER: CRD420251180854.
引用
- Bujak, Laudani, Rinaldi, et al. Optimal timing of aspirin discontinuation after acute coronary syndrome treated with percutaneous coronary intervention: a systematic review and meta-analysis. Heart. 2026. PMID: 42362365. doi:10.1136/heartjnl-2026-328334
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。